Is Etoricoxib registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 54 valid registrations of Etoricoxib, including ARCOXIA 120MG TAB (120 mg, Film-coated tablet, SAR 18.60); ARCOXIA 60MG TAB (60 mg, Film-coated tablet, SAR 70.70); ARCOXIA 90MG TAB (90 mg, Film-coated tablet, SAR 70.70); ARGENTA (120 mg, Film-coated tablet, SAR 11.00); ARGENTA (90 mg, Film-coated tablet, SAR 41.00).

Are there safety signals or safety updates for Etoricoxib?

MHRA: 2 entries (latest 2016-10-17).

Active substance

Etoricoxib

SFDA 61
NHS prices 4
Safety 2

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
ARCOXIA 120MG TAB	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 18.60	NCE · Prescription	N.V. Organon	Valid
ARCOXIA 60MG TAB	60 mg	Film-coated tablet · Oral use	28 Blister	SAR 70.70	NCE · Prescription	N.V. Organon	Valid
ARCOXIA 90MG TAB	90 mg	Film-coated tablet · Oral use	28 Blister	SAR 70.70	NCE · Prescription	N.V. Organon	Valid
ARGENTA	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 11.00	Generic · Prescription	ALPHA PHARMA INDUSTRY	Valid
ARGENTA	90 mg	Film-coated tablet · Oral use	28 Blister	SAR 41.00	Generic · Prescription	ALPHA PHARMA INDUSTRY	Valid
ARGENTA	60 mg	Film-coated tablet · Oral use	28 Blister	SAR 41.00	Generic · Prescription	ALPHA PHARMA INDUSTRY	Valid
ARXIA 120MG F.C.TABLET	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 11.00	Generic · Prescription	LABORATORIOS CINFA SA	Valid
ARXIA 60MG F.C.TABLET	60 mg	Film-coated tablet · Oral use	28 Blister	SAR 41.10	Generic · Prescription	LABORATORIOS CINFA SA	Valid
ARXIA 90MG F.C.TABLET	90 mg	Film-coated tablet · Oral use	28 Blister	SAR 41.10	Generic · Prescription	LABORATORIOS CINFA SA	Valid
ATOX	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 11.00	Generic · Prescription	DAMMAM PHARMA	Valid
ATOX	90 mg	Film-coated tablet · Oral use	28 Blister	SAR 41.00	Generic · Prescription	DAMMAM PHARMA	Valid
ATOX	60 mg	Film-coated tablet · Oral use	28 Blister	SAR 41.00	Generic · Prescription	DAMMAM PHARMA	Valid
ATOXIA 120 mg Film-coated Tablet	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 11.00	Generic · Prescription	MS Pharma Saudi (MSPS)	Valid
ATOXIA 60 mg Film-coated Tablet	60 mg	Film-coated tablet · Oral use	10 Blister	SAR 14.65	Generic · Prescription	MS Pharma Saudi (MSPS)	Valid
ATOXIA 90 mg Film-coated Tablet	90 mg	Film-coated tablet · Oral use	10 Blister	SAR 14.65	Generic · Prescription	MS Pharma Saudi (MSPS)	Valid
Arkator 120MG F.C.TABLET	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 13.60	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
Arkator 60MG F.C.TABLET	60 mg	Film-coated tablet · Oral use	28 Blister	SAR 54.40	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
Arkator 90MG F.C.TABLET	90 mg	Film-coated tablet · Oral use	28 Blister	SAR 54.40	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
CORREX 120MG F.C.TABLET	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 11.00	Generic · Prescription	Al-Taqaddom pharmaceutical Industries	Valid
CORREX 90MG F.C.TABLET	90 mg	Film-coated tablet · Oral use	14 Blister	SAR 19.15	Generic · Prescription	Al-Taqaddom pharmaceutical Industries	Valid
Correx	90 mg	Film-coated tablet · Oral use	28 Blister	SAR 41.00	Generic · Prescription	Al-Taqaddom pharmaceutical Industries	Valid
ETORIA 120MG FILM COATED TABLETS	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 15.10	Generic · Prescription	SPIMACO ADDWAEIH	Valid
ETORIA 60MG FILM COATED TABLETS	60 mg	Film-coated tablet · Oral use	28 Blister	SAR 60.45	Generic · Prescription	SPIMACO ADDWAEIH	Valid
ETORIA 90MG FILM COATED TABLETS	90 mg	Film-coated tablet · Oral use	28 Blister	SAR 60.45	Generic · Prescription	SPIMACO ADDWAEIH	Valid
ETOXA 120 MG FILM COATED TABLET	120 mg	Film-coated tablet · Oral use	7 Blister	SAR 12.25	Generic · Prescription	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid

36 more — full table

Indications — CHI Daman Drug Formulary

ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; CHRONIC PANCREATITIS; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; GOUT; JUVENILE IDIOPATHIC ARTHRITIS (JIA); LOW BACK PAIN; MENSTRUAL DISORDERS; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS; SICKLE CELL DISEASE - PAIN MANAGEMENT

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
NHS Drug Tariff	Etoricoxib 120mg tablets	£3.01	28 tablet	1 Oct 2026
NHS Drug Tariff	Etoricoxib 30mg tablets	£1.50	28 tablet	1 Oct 2026
NHS Drug Tariff	Etoricoxib 60mg tablets	£1.82	28 tablet	1 Oct 2026
NHS Drug Tariff	Etoricoxib 90mg tablets	£2.10	28 tablet	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

MHRA 17 Oct 2016 Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis
Prescribing information has been updated to introduce a lower recommended dose of 60 mg daily for patients with rheumatoid arthritis or ankylosing spondylitis.
MHRA 11 Dec 2014 Etoricoxib: prescribing to patients with high blood pressure
Do not prescribe etoricoxib to patients whose blood pressure is persistently above 140/90 mmHg and inadequately controlled.

All safety entries for etoricoxib →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.